"Glioma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Descriptor ID |
D005910
|
| MeSH Number(s) |
C04.557.465.625.600.380 C04.557.470.670.380 C04.557.580.625.600.380
|
| Concept/Terms |
Glioma- Glioma
- Gliomas
- Glial Cell Tumors
- Glial Cell Tumor
- Tumor, Glial Cell
- Tumors, Glial Cell
Mixed Glioma- Mixed Glioma
- Glioma, Mixed
- Gliomas, Mixed
- Mixed Gliomas
Malignant Glioma- Malignant Glioma
- Glioma, Malignant
- Gliomas, Malignant
- Malignant Gliomas
|
Below are MeSH descriptors whose meaning is more general than "Glioma".
Below are MeSH descriptors whose meaning is more specific than "Glioma".
This graph shows the total number of publications written about "Glioma" by people in this website by year, and whether "Glioma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 2 | 5 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 3 | 2 | 5 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 0 | 5 |
| 2008 | 12 | 0 | 12 |
| 2009 | 9 | 1 | 10 |
| 2010 | 19 | 1 | 20 |
| 2011 | 13 | 3 | 16 |
| 2012 | 8 | 0 | 8 |
| 2013 | 13 | 2 | 15 |
| 2014 | 10 | 2 | 12 |
| 2015 | 12 | 0 | 12 |
| 2016 | 10 | 1 | 11 |
| 2017 | 13 | 1 | 14 |
| 2018 | 10 | 1 | 11 |
| 2019 | 14 | 1 | 15 |
| 2020 | 8 | 2 | 10 |
| 2021 | 14 | 0 | 14 |
| 2022 | 20 | 0 | 20 |
| 2023 | 22 | 0 | 22 |
| 2024 | 15 | 4 | 19 |
| 2025 | 14 | 0 | 14 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glioma" by people in Profiles.
-
Hp1bp3 loss links chromatin reorganization to metabolic vulnerability in glioma. Proc Natl Acad Sci U S A. 2026 Jun 16; 123(24):e2601061123.
-
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs. Nat Genet. 2026 Jun; 58(6):1368-1382.
-
EZHIP boosts neuronal-like synaptic gene programs and depresses polyamine metabolism. Acta Neuropathol Commun. 2025 11 07; 13(1):227.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Tumor Expression of CD83 Reduces Glioma Progression and Is Associated with Reduced Immunosuppression. Cancer Res Commun. 2024 12 01; 4(12):3209-3223.
-
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025 01; 637(8046):708-715.
-
Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas. Acta Oncol. 2024 Oct 20; 63:798-804.
-
CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas. Br J Cancer. 2024 Jul; 131(2):258-270.
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 08 10; 42(23):2769-2779.
-
Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma. J Clin Invest. 2024 Jan 16; 134(2).